Member Info for Lebus

Makes my left eye twitch uncontrollably haha

A cash raise at what, 25p per share maybe. Doesn’t bear thinking about for those who invested heavily to finance the ph 3 at 175p

“Would anyone else do any better” Well, I reckon Pfizer or GSK would have taken less than nearly two decades to either 1. Get this product licensed for use or 2. Write it off is ineffective and move on

Sharedealer - re your football analogy. RM is the Manager, not the goalkeeper. He has had nigh on 20 years to produce results and won nothing yet. You don’t last long in football management with his record

Spot on Aether

Finance a new trial? Those of us who financed the phase 3 at 175p might feel reluctant to make a further investment at 35p - 40p Just a personal perspective

Dactions, are you aware whether that twitter post received a response from Synairgen?

Just hope Polygon takes a similar view

Fair enough observation, but it’s perfectly legitimate for someone to hold shares in this business because they are persuaded by the potential of the drug, whilst at the same time criticising the CEO because of the abject/avoidable failure of a trial conducted on his watch

B2HS2L - Don’t just focus on big pharma though. I mentioned a few months ago that like it or not, this business would be a perfect fit for Phillip Morris International. As part of their “smoke free future” mission, they are on the hunt for respiratory drug businesses. They bought Otitopic and Vectura in 2021. Any Inhaled therapeutics/research businesses will be in their crosshairs, and given Synairgens market value at the moment, PM could absorb this Company into their portfolio just by dipping into their tea fund money

Andyb4 and MrCosts make perfectly valid points in my view. This most recent interview with RM was disgraceful. Who is going to take responsibility for this badly designed trial? Well, no one as yet. It all seems to be business as usual. More trials, maybe veer back to COPD blah blah.
I can only hope that Polygon are making discreet approaches to players with big pharma experience before starting manoeuvres to oust this hapless CEO.
RM needs reminding that one of his principal responsibilities is to maximise returns for shareholders. At the moment he is only maximising returns for himself and other members of his team who contributed to this trial debacle.

Ndn has taken some stick from some posters over the course of the last few months, but he’s the only one who got even close to anticipating this possible outcome.

Fair play to you

No problem buying through HL.

And if they don’t have time to get back to you - let’s leave em to get on with it

Fizzy - if you get a reply confirming 1. Date Sprinter trial results to be announced 2. And/or T/O plans. Please share. That would be helpful.

PM also bought OtiTopic last summer - another respiratory drug Company. They are on the hunt to boost the credibility of their smoke free mission statement, and with a huge war chest. Synairgen must be in their cross hairs.

Guess we will find out soon one way or another

If Polygon are accumulating on behalf of a client, my money is on Philip Morris International.

Synairgen features in Questor shares report. Not surprisingly notes that sp will either soar or slump depending on outcome of phase 3 trial. Hold recommendation

Any low volume of daily trades allows B of A to marshall the market but the bottom line is that they are accumulating

Bank of America now increased to 7.8%. Sold to reduce price per share and then buy at a cheaper rate. They ain’t going away